株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ワクチン受託製造市場:第2版 (2019-2030年)

Vaccine Contract Manufacturing Market (2nd Edition), 2019 - 2030

発行 ROOTS ANALYSIS 商品コード 362820
出版日 ページ情報 英文 406 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
ワクチン受託製造市場:第2版 (2019-2030年) Vaccine Contract Manufacturing Market (2nd Edition), 2019 - 2030
出版日: 2019年07月19日 ページ情報: 英文 406 Pages
概要

当レポートでは、世界のワクチン受託製造の市場を調査し、ワクチンおよびワクチン製造の概要、競合環境・主要CMOのプロファイル、サービスポートフォリオ・発現系・操業規模・企業規模・地域/主要国など各種区分別の市場規模の推移と予測、ワクチン需要・製造能力・企業間提携動向などの分析、専門家による見解、将来の展望などをまとめています。

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 本章の概要
  • ワクチンの分類:有効成分別
    • 弱毒生ワクチン
    • 不活化ワクチン
    • サブユニットワクチン
    • トキソイドワクチン
    • DNAワクチン
  • ワクチンの組成と主要コンポーネント
  • ワクチンの開発・製造
    • 抗原の特定と製造プロセスの開発
    • ワクチン製造:発現系別
    • 製造プロセス
    • 臨床開発と承認
    • サプライチェーン・流通
  • 受託製造:定義

第4章 競合環境

  • 本章の概要
  • 受託製造業者

第5章 企業の競争力

  • 本章の概要
  • 前提因子・主要パラメーター
  • 競争力の分析:北米のワクチン受託製造業者
    • 哺乳類発現系
    • 微生物発現系
    • 他の発現系
  • 競争力の分析:欧州のワクチン受託製造業者
    • 哺乳類発現系
    • 微生物発現系
    • 他の発現系
  • 競争力の分析:アジア太平洋・その他の地域のワクチン受託製造業者
    • 哺乳類発現系
    • 微生物発現系
    • 他の発現系

第6章 北米のワクチン受託製造業者

  • 本章の概要
  • Albany Molecular Research (AMRI) / OSO BioPharmaceuticals Manufacturing (OsoBio)
  • Catalent Biologics
  • Charles River Laboratories
  • Meridian Life Science (MLS)
  • BioReliance (A Unit of Merck)
    • 企業概要
    • 財務情報
    • 製造サービスポートフォリオ
    • 製造設備
    • 近年の展開
    • 将来の展望、など

第7章 欧州のワクチン受託製造業者

  • 本章の概要
  • Cobra Biologics
  • Eurogentec
  • IDT Biologika
  • Lonza
    • 企業概要
    • 財務情報
    • 製造サービスポートフォリオ
    • 製造設備
    • 近年の展開
    • 将来の展望、など

第8章 アジア太平洋・その他の地域のワクチン受託製造業者

  • 本章の概要
  • GreenPak Biotech
  • Hong Kong Institute of Biotechnology
  • WuXi AppTec (WuXi Biologics)
  • Bharat Biotech
  • Biological E
    • 企業概要
    • 財務情報
    • 製造サービスポートフォリオ
    • 製造設備
    • 近年の展開
    • 将来の展望、など

第9章 提携・協力

  • 本章の概要
  • 提携モデル
  • 提携・協力リスト

第10章 近年の拡張動向

第11章 製造能力の分析

  • 本章の概要
  • 世界の製造能力
  • 総論

第12章 ワクチン需要の分析

第13章 市場予測

  • 本章の概要
  • 総市場の予測
  • 市場予測:サービスポートフォリオ別
  • 市場予測:発現系別
  • 市場予測:操業規模別
  • 市場予測:企業規模別
  • 市場予測:地域・主要国別

第14章 SWOT分析

第15章 将来の動向

第16章 専門家による見解

第17章 付録:図表データ

第18章 付録:企業・組織リスト

目次

Example Insights:

Over 70 companies based in different regions across the globe claim to provide contract development, fill / finish and regulatory services in addition to manufacturing various types of vaccines.

The market landscape includes both established players and new entrants, operating at various scales and capable of manufacturing vaccines based on a variety of expression systems.

The extent of activity in this field is reflected in the number of partnerships, which have been focused on a diverse range of vaccines, and involve both international and indigenous industry stakeholders.

Overview:

The global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025. According to the WHO, the global vaccination rate is nearly 85%, demonstrating the high clinical demand for vaccines. In addition to meeting the growing demand for vaccines, the developers of these pharmacological interventions are also plagued by high costs of development and complex production protocols. Given that vaccine manufacturing requires highly regulated, state-of-the-art technologies, it has become increasingly difficult for stakeholders to establish in-house expertise for large-scale manufacturing of vaccines. As a result, vaccine developers have begun outsourcing their manufacturing operations to contract manufacturing organizations (CMOs). Specifically, small and mid-sized players in this sector tend to outsource a substantial proportion of clinical development and commercial-scale manufacturing processes to contract service providers. In addition, even big pharma players, with established in-house capabilities, are gradually entering into long-term business relationships with CMOs in order to optimize resource utilization and manage costs.

It is worth highlighting that the contemporary contract services market for vaccines is highly fragmented. Having said that, numerous stakeholders are actively striving to expand their respective service portfolios through substantial acquisition activity. As a result, these CMOs have developed the capabilities to offer end-to-end services, ranging from vaccine development (including preliminary R&D, preclinical studies and clinical trials), to regulatory filings, and commercial scale production. In future, we expect the demand for core competencies to continue to drive sponsor companies to rely on contract service providers for various aspects of product development and manufacturing. Amidst tough competition, the availability of cutting-edge tools and technologies has emerged as a differentiating factor and is likely to grant a competitive advantage to certain CMOs over other players in the industry.

Scope of the Report:

The “Vaccine Contract Manufacturing Market (2nd Edition), 2019 - 2030” report features an extensive study on contract service providers engaged in the development and manufacturing of vaccines. The study features in-depth analyses, highlighting the capabilities of various vaccine CMOs. Amongst other elements, the report includes:

  • A detailed review of the contract manufacturing landscape for vaccines, featuring a comprehensive list of active CMOs and analysis based on a number of parameters, such as year of establishment, company size, geographical location, number of vaccine manufacturing facilities, types of services offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings), scale of operation (preclinical, clinical and commercial), type of expression systems used (mammalian, microbial and others) and type(s) of vaccines manufactured.
  • A region-wise, company competitiveness analysis, highlighting prominent vaccine contract manufacturers based on supplier strength (considering the experience of the contract manufacturer), and service strength (which takes into account the count of service offerings, number of expression systems used and scale of operation).
  • Elaborate profiles of the key players based in North America, Europe and Asia-Pacific that have a diverse range of capabilities for the development, manufacturing and packaging of vaccines. Each profile includes an overview of the company, its financial performance (if available), information on service portfolio, vaccine manufacturing facilities, and details on partnerships, recent developments (expansions), and awards and accolades received, as well as an informed future outlook.
  • An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of vaccines, based on various parameters, such as year of agreement, type of agreement, scale of operation, types of services mentioned in the deal, types of vaccines manufactured, types of therapeutic area and location of facility where the project is to be executed.
  • A detailed analysis of the expansions undertaken (since 2013) by various service providers within vaccine contract manufacturing industry, based on a number of parameters, including year of expansion, type of expansion (capacity expansion, capability expansion and new facility), geographical location of facility, scale of operation, types of services involved, expansion details (in terms of new area added to existing facilities, if available) and most active players (in terms of number of instances).
  • An informed estimate of the annual demand for vaccines (in mL), taking into account the 20 top selling vaccines, based on various parameters, such as target patient population, dosing frequency and dose strength.
  • A detailed capacity analysis, taking into consideration the manufacturing capacities of various stakeholders (small-sized, mid-sized, large and very large CMOs) in the market, based on data gathered via secondary and primary research. It also provides the distribution of global vaccine manufacturing capacity by company size (small-sized, mid-sized, large and very large), and geography (North America, Europe and Asia-Pacific) and scale of operation (preclinical / clinical and commercial).
  • A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry's evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.
  • A discussion on the potential market drivers, such as the growing vaccines pipeline, increasing outsourcing of vaccine operations and opportunities in Asia-Pacific region, which are likely to present in the coming years.

One of the key objectives of the report was to estimate the future size of the market. Based on the parameters, such as growth of the overall vaccine market, cost of goods sold, and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period, 2019-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] commonly outsourced vaccine-related operations (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings) [B] types of expression systems (mammalian, microbial and others), [C] size of contract service provider company (small-sized, mid-sized and large / very large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America (US, Canada), Europe (UK, France, Germany, Italy and Spain), Asia (China and India) and rest of the world. To account for the uncertainties associated with the manufacturing of vaccines and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Menzo Havenga, CEO, Batavia Biosciences and Claire Otjes, Marketing Manager, Batavia Biosciences
  • David C Cunningham, Director Corporate Development, Goodwin Biotechnology
  • Ingrid Cromann, Director - Vaccine Development, Statens Serum Institut
  • Kevin Daley, Director Pharmaceuticals, Novasep Synthesis
  • Oliver Schub, Senior Business Development Manager, ProBioGen
  • Sebastian Schuck, Head of Business Development, Wacker Biotech

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines:

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the vaccine contract manufacturing market in the mid to long term.

Chapter 3 provides a general introduction to vaccines. The chapter also includes an overview of the various expression systems used in the development and manufacturing of vaccines. It also features a brief overview of contract manufacturing and a detailed discussion on the need for outsourcing within the vaccines industry. The chapter includes a list of commonly outsourced vaccine manufacturing services, and concludes with a discussion on the challenges that are currently associated within this market.

Chapter 4 provides a comprehensive overview of the global vaccine contract manufacturing landscape. It includes information related to over 70 CMOs that are currently active in this domain. In addition, it features an in-depth analysis of the market, based on a number of parameters, such as the year of establishment, company size, geographical location, number of vaccine manufacturing facilities, types of services offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings), scale of operation (preclinical, clinical and commercial), type of expression systems used (mammalian, microbial and others) and type(s) of vaccines manufactured.

Chapter 5 features a comprehensive company competitiveness analysis of vaccine contract manufacturers based in North America, Europe and Asia-Pacific, that we came across during our research. The analysis compares companies within each geography on the basis of supplier strength (considering the experience of contract manufacturer) and service strength (which takes into account the count of service offerings, number of expression systems used, and scale of operation).

Chapter 6 provides detailed profiles of some of the key players that are active in the vaccine contract manufacturing market in North America. Each profile presents a brief overview of the company, financial information (if available), its contract service offerings highlighting the capabilities of vaccine product facilities, recent developments and an informed future outlook.

Chapter 7 provides detailed profiles of some of the key players that are active in the vaccine contract manufacturing market in Europe. Each profile presents a brief overview of the company, financial information (if available), its contract service offerings highlighting the capabilities of vaccine product facilities, recent developments and an informed future outlook.

Chapter 8 provides detailed profiles of some of the key players that are active in the vaccine contract manufacturing market in Asia-Pacific. Each profile presents a brief overview of the company, financial information (if available), its contract service offerings highlighting the capabilities of vaccine product facilities, recent developments and an informed future outlook.

Chapter 9 features an elaborate analysis and discussion on the collaborations and partnerships that have been inked amongst players, since 2013. It includes brief descriptions of the various partnership models (including acquisition, distribution agreement, licensing agreements, manufacturing, product development / commercialization, product development and manufacturing, process development and manufacturing, process development, R&D agreements, service alliance and others) that have been adopted by stakeholders in this domain. It also includes analysis based on year of agreement, type of agreement, scale of operation, types of services mentioned in the deal, types of vaccines manufactured, types of therapeutic area and location of facility where the project is to be executed. Further, the chapter features a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 10 presents detailed analysis on the expansions that have taken place in the vaccine manufacturing industry, since 2013. It includes information on expansions for increasing existing capabilities, as well as setting-up of new facilities by service provider entities engaged in this domain. The expansion instances that we came across were analyzed based on various parameters, including year of expansion, type of expansion (capacity expansion, capability expansion and new facility), geographical location of the facility, scale of operation (as mentioned in the expansion terms), types of services involved, expansion details (in terms of new area added to the existing facilities, if available) and also highlights the most active players (in terms of number of instances) in the domain.

Chapter 11 features an analysis of the global / regional capacity of contract manufacturers that are engaged in the manufacturing of vaccine products. The analysis takes into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, large and very large CMOs) in the market, using data from both secondary and primary research. The study examines the distribution of global vaccine manufacturing capacity by size of the company (small-sized, mid-sized, large and very large), region of operation (North America Europe Asia and Middle East and, rest of the world and scale of operation (preclinical / clinical, commercial).

Chapter 12 features an informed view on the demand for vaccines (both clinical and commercially available) in the market, offering an informed opinion on the required scale of supply (in terms of vaccine manufacturing services). For the purpose of estimating the current clinical demand, we considered the active clinical studies of different types of vaccines that have been registered since 1971. The data was analyzed on the basis of various parameters, such as number of annual clinical doses, trial location, leading industry / non-industry sponsors, and the enrolled patient population across different geographies. Further, in order to estimate the commercial demand, we considered the top 20 vaccines, based on a various parameters, such as target patient population, dosing frequency and dose strength.

Chapter 13 presents an insightful market forecast analysis, highlighting the likely growth of the vaccine contract manufacturing market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] commonly outsourced vaccine-related operations (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings) [B] types of expression systems (mammalian, microbial and others) [C] size of the company (small-sized, mid-sized and large / very large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America (US, Canada), Europe (UK, France, Germany, Italy and Spain), Asia (China and India) and rest of the world (Australia)).

Chapter 14 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of biopharmaceuticals manufacturing market, under a comprehensive SWOT framework.

Chapter 15 highlights the potential growth drivers for contract vaccine manufacturers. It highlights the various opportunities associated with the growing vaccine pipeline, increase in outsourcing of vaccine manufacturing operations, adoption of innovative technologies and opportunities in Asia-Pacific region, which are likely to have a notable influence on the future of the vaccine contract manufacturing market.

Chapter 16 features the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the vaccine contract manufacturing domain. We spoke to Menzo Havenga (CEO, Batavia Biosciences) and Claire Otjes (Marketing Manager, Batavia Biosciences), David C Cunningham (Director Corporate Development, Goodwin Biotechnology), Ingrid Cromann (Director - Vaccine Development, Statens Serum Institut), Kevin Daley (Director Pharmaceuticals, Novasep Synthesis), Oliver Schub (Senior Business Development Manager, ProBioGen) and Sebastian Schuck (Head of Business Development, Wacker Biotech).

Chapter 17 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 18 is an appendix that provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Classification of Vaccines based on the Type of Active Ingredient
    • 3.2.1. Live, Attenuated Vaccines
    • 3.2.2. Inactivated Vaccines
    • 3.2.3. Subunit Vaccines
    • 3.2.4. Toxoid Vaccines
    • 3.2.5. DNA Vaccines
  • 3.3. Key Components within Vaccine Formulations
  • 3.4. Vaccine Development and Manufacturing
    • 3.4.1. Identification of Antigen and Manufacturing Process Development
    • 3.4.2. Production of Vaccines in Different Expression System
      • 3.4.2.1. Bacterial Expression System
      • 3.4.2.2. Yeast Expression System
      • 3.4.2.3. Insect Expression
      • 3.4.2.4. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)
      • 3.4.2.5. Plant Expression Systems
      • 3.4.2.6. Avian Expression Systems
      • 3.4.2.7. Mammalian Expression Systems
    • 3.4.3. Vaccine Manufacturing Process
      • 3.4.3.1. Upstream Process
      • 3.4.3.2. Downstream Process
      • 3.4.3.3. Formulation and Fill / Finish
    • 3.4.4. Clinical Development and Approval
    • 3.4.5. Vaccine Supply Chain and Logistics
  • 3.5. Vaccine Contract Manufacturing
    • 3.5.1. Need for Outsourcing Vaccine Manufacturing Operations
    • 3.5.2. Commonly Outsourced Operations
    • 3.5.3. Selecting a CMO Partner
    • 3.5.4. Advantages of Outsourcing Manufacturing Operations
    • 3.5.5. Risk Factors and Challenges

4. COMPETITIVE LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Vaccine Contract Manufacturers: Overall Market Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Size of Employee Base
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Analysis by Location of Manufacturing Facilities
    • 4.2.5. Analysis by Type of Services Offered
    • 4.2.6. Analysis by Scale of Operation
    • 4.2.7. Analysis by Expression System Used
    • 4.2.8. Analysis by Type of Vaccines Manufactured

5. COMPANY COMPETITIVE ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Methodology
  • 5.3. Assumptions and Key Input Parameters
  • 5.4. Competitiveness Analysis: Vaccine Contract Manufacturers in North America
    • 5.4.1. Companies Offering Contract Vaccine Manufacturing Services based on Mammalian Expression System
    • 5.4.2. Companies Offering Contract Vaccine Manufacturing Services based on Microbial Expression System
    • 5.4.3. Companies Offering Contract Vaccine Manufacturing Services based on Other Expression System
  • 5.5. Competitiveness Analysis: Vaccine Contract Manufacturers in Europe
    • 5.5.1. Companies Offering Contract Vaccine Manufacturing Services based on Mammalian Expression System
    • 5.5.2. Companies Offering Contract Vaccine Manufacturing Services based on Microbial Expression System
    • 5.5.3. Companies Offering Contract Vaccine Manufacturing Services based on Other Expression System
  • 5.6. Competitiveness Analysis: Vaccine Contract Manufacturers in Asia-Pacific and Rest of the World
    • 5.6.1. Companies Offering Contract Vaccine Manufacturing Services based on Mammalian Expression System
    • 5.6.2. Companies Offering Contract Vaccine Manufacturing Services based on Microbial Expression System
    • 5.6.3. Companies Offering Contract Vaccine Manufacturing Services based on Other Expression System

6. VACCINE CONTRACT MANUFACTURING IN NORTH AMERICA

  • 6.1. Chapter Overview
  • 6.2. Albany Molecular Research (AMRI) / OSO BioPharmaceuticals Manufacturing (OsoBio)
    • 6.2.1. Company Overview
    • 6.2.2. Financial Information
    • 6.2.3. Vaccine Manufacturing Services Portfolio
      • 6.2.3.1. Fill / Finish Services
      • 6.2.3.2. Regulatory Support and Quality Assurance Services
    • 6.2.4. Vaccine Manufacturing Facilities
    • 6.2.6. Recent Developments
      • 6.2.6.1. Partnerships
      • 6.2.6.2. Expansions
      • 6.2.6.3. Awards and Accolades
    • 6.2.7. Future Outlook
  • 6.3. Catalent Biologics
    • 6.3.1. Company Overview
    • 6.3.2. Financial Information
    • 6.3.3. Vaccine Manufacturing Services Portfolio
      • 6.3.3.1. Cell Line Development Services
      • 6.3.3.2. Clinical Manufacturing Services
      • 6.3.3.3. Analytical Services
      • 6.3.3.4. Clinical Supply Services
      • 6.3.3.5. Regulatory Support Services
    • 6.3.4. Vaccine Manufacturing Facilities
    • 6.3.5. Recent Developments
      • 6.3.5.1. Partnerships
      • 6.3.5.2. Expansions
      • 6.3.5.3. Awards and Accolades
    • 6.3.6. Future Outlook
  • 6.4. Charles River Laboratories
    • 6.4.1. Company Overview
    • 6.4.2. Financial Information
    • 6.4.3. Vaccine Manufacturing Services Portfolio
      • 6.4.3.1. Vaccine Development Services
      • 6.4.3.2. Vaccine Manufacturing Services
      • 6.4.3.3. Avian Vaccine Services
    • 6.4.4. Vaccine Manufacturing Facilities
    • 6.4.5. Recent Developments
      • 6.4.5.1. Partnerships
      • 6.4.5.2. Expansions
    • 6.4.6. Future Outlook
  • 6.5. Meridian Life Science (MLS)
    • 6.5.1. Company Overview
    • 6.5.2. Financial Information
    • 6.5.3. Vaccine Manufacturing Services Portfolio
      • 6.5.3.1. Cell and Virus Banking Services
      • 6.5.3.2. Process development and Scale-up Services
      • 6.5.3.3. Formulation Development and Fill / finish Services
      • 6.5.3.4. Regulatory Support Services
    • 6.5.4. Vaccine Manufacturing Facilities
    • 6.5.5. Recent Developments
      • 6.5.5.1. Partnerships
      • 6.5.5.2. Awards and Accolades
    • 6.5.6. Future Outlook
  • 6.6. BioReliance (A Unit of Merck)
    • 6.6.1. Company Overview
    • 6.6.2. Financial Information
    • 6.6.3. Vaccine Manufacturing Services Portfolio
      • 6.6.3.1. cGMP Cell and Virus Banking Services
      • 6.6.3.2. Process Development Services
      • 6.6.3.3. Biorepository Services
      • 6.6.3.4. Contract Manufacturing Support Services
    • 6.6.4. Vaccine Manufacturing Facilities
    • 6.6.5. Recent Developments
      • 6.6.5.1. Partnerships
      • 6.6.5.2. Expansions
      • 6.6.5.3. Awards and Accolades
    • 6.6.6. Future Outlook

7. VACCINE CONTRACT MANUFACTURING IN EUROPE

  • 7.1. Chapter Overview
  • 7.2. Cobra Biologics
    • 7.2.1. Company Overview
    • 7.2.2. Vaccine Manufacturing Services Portfolio
      • 7.2.2.1. Viral Vaccines and Virus based Services
      • 7.2.2.2. DNA Vaccines and DNA based Services
      • 7.2.2.3. Other Services
    • 7.2.3. Vaccine Manufacturing Facilities
    • 7.2.4. Recent Developments
      • 7.2.4.1. Partnerships
      • 7.2.4.2. Expansions
    • 7.2.5. Future Outlook
  • 7.3. Eurogentec
    • 7.3.1. Company Overview
    • 7.3.2. Vaccine Manufacturing Services Portfolio
      • 7.3.2.1. Manufacturing Services
      • 7.3.2.2. Analytical and Regulatory Support Services
      • 7.3.2.3. Other Services
    • 7.3.3. Future Outlook
  • 7.4. IDT Biologika
    • 7.4.1. Company Overview
    • 7.4.2. Vaccine Manufacturing Services Portfolio
      • 7.4.2.1. Development Services
      • 7.4.2.2. Vaccine Manufacturing Services
      • 7.4.2.3. Fill / Finish Services
      • 7.4.2.4. Labeling and Packaging Services
      • 7.4.2.5. Storage Services
      • 7.4.2.6. Quality Control Services
    • 7.4.3. Vaccine Manufacturing Facilities
    • 7.4.4. Recent Developments
      • 7.4.4.1. Partnerships
      • 7.4.4.2. Expansions
      • 7.4.4.3. Awards and Accolades
    • 7.4.5. Future Outlook
  • 7.6. Lonza
    • 7.6.1. Company Overview
    • 7.6.2. Financial Information
    • 7.6.3. Vaccine Manufacturing Services Portfolio
      • 7.6.3.1. Process Development and Optimization Services
      • 7.6.3.2. Vaccine Commercial Manufacturing Services
      • 7.6.3.3. Fill / Finish Services
      • 7.6.3.4. Other Services
    • 7.6.4. Recent Developments
      • 7.6.4.1. Partnerships
      • 7.6.4.2. Expansions
      • 7.6.4.3. Awards and Accolades
    • 7.6.5. Future Outlook

8. VACCINE CONTRACT MANUFACTURING IN ASIA PACIFIC AND THE REST OF THE WORLD

  • 8.1. Chapter Overview
  • 8.2. GreenPak Biotech
    • 8.2.1. Company Overview
    • 8.2.2. Vaccine Manufacturing Services Portfolio
  • 8.3. Hong Kong Institute of Biotechnology
    • 8.3.1. Company Overview
    • 8.3.2. Vaccine Manufacturing Services Portfolio
      • 8.3.2.1. Manufacturing Services
    • 8.3.3. Vaccine Manufacturing Facilities
  • 8.4. WuXi AppTec ((WuXi Biologics)
    • 8.4.1. Company Overview
    • 8.4.2. Financial Information
    • 8.4.3. Vaccine Manufacturing Services Portfolio
      • 8.4.3.1. Non-Clinical Services
      • 8.4.3.2. Discovery and Early Diagnostic Testing Services
      • 8.4.3.3. Support Services
      • 8.4.3.4. Manufacturing Services
      • 8.4.3.5. Vaccine Testing Services
    • 8.4.4. Recent Developments
      • 8.4.4.1. Partnerships
      • 8.4.4.2. Awards and Accolades
    • 8.4.5. Future Outlook
  • 8.5. Bharat Biotech
    • 8.5.1. Company Overview
    • 8.5.2. Vaccine Manufacturing Services Portfolio
    • 8.5.3. Vaccine Manufacturing Facilities
    • 8.5.4. Recent Developments
      • 8.5.4.1. Partnerships
      • 8.5.4.2. Awards and Accolades
    • 8.5.5. Future Outlook
  • 8.6. Biological E
    • 8.6.1. Company Overview
    • 8.6.2. Vaccine Manufacturing Services Portfolio
    • 8.6.3. Vaccine Manufacturing Facilities
    • 8.6.4. Recent Developments
      • 8.6.4.1. Partnerships
      • 8.6.4.2. Expansions
      • 8.6.4.3. Awards and Accolades
    • 8.6.5. Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. Vaccine Contract Manufacturing: List of Partnerships and Collaborations
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Focus Area
    • 9.3.4. Analysis by Scale of Operation
    • 9.3.5. Most Active Players: Analysis by Number of Partnerships
    • 9.3.6. Regional Analysis
      • 9.3.6.1. Intercontinental and Intracontinental Agreements

10. RECENT EXPANSIONS

  • 10.1. Chapter Overview
    • 10.1.1. Vaccine Contract Manufacturing Service Providers: Recent Expansions
    • 10.1.2. Analysis by Year of Expansion
    • 10.1.3. Analysis by Type of Expansion
    • 10.1.4. Analysis by Scale of Operation and Type of Expansion
    • 10.1.5. Analysis by Geographical Distribution
    • 10.1.6. Analysis by Company Headquarters and Company Size
    • 10.1.7. Analysis by Location of Facility and Purpose of Expansion
    • 10.1.8. Analysis by Type of Services Offered
    • 10.1.9. Analysis by Type of Service and Purpose of Expansion
    • 10.1.10. Most Active Players: Analysis by Number of Recent Expansions

11. CAPACITY ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Assumptions and Methodology
  • 11.3. Vaccine Contract Manufacturing Market: Global Production Capacity (in Liters) 11.3.1.
    • 11.3.2. Analysis by Expression System
    • 11.3.3. Analysis by Scale of Operation
    • 11.3.4. Analysis by Region
      • 11.3.4.1. Production Capacity in North America (in Liters)
      • 11.3.4.2. Production Capacity in Europe (in Liters)
      • 11.3.4.3. Production Capacity in Asia and Middle East (in Liters)
  • 11.4. Conclusion

12. DEMAND ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Scope and Methodology
  • 12.3. Global Clinical Demand for Vaccines: Analysis by Number of Trials
    • 12.3.1. Analysis by Trial Registration Year
    • 12.3.2. Analysis by Type of Vaccine
    • 12.3.3. Analysis by Clinical Dose
    • 12.3.4. Analysis by Trial Status
    • 12.3.5. Geographical Analysis by Number of Clinical Trials
    • 12.3.6. Geographical Analysis by Trial Status and Trial Phase
    • 12.3.7. Analysis by Type of Sponsors / Collaborators
    • 12.3.8. Most Active Players
  • 12.4. Global Clinical Demand for Vaccines: Analysis by Enrolled Patient Population
    • 12.4.1. Geographical Analysis by Enrolled Patient Population
    • 12.4.2. Geographical Analysis of Enrolled Patient Population by Trial Phase and Type of Vaccine
  • 12.5. Global Clinical Demand for Vaccines: Annual Demand of Vaccines
  • 12.6. Concluding Remarks

13. MARKET FORECAST

  • 13.1. Chapter Overview
  • 13.2. Forecast Methodology and Key Assumptions
  • 13.3. Overall Vaccine Contract Manufacturing Market, 2019-2030
  • 13.4. Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Service Portfolio
  • 13.5. Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Expression System Used
  • 13.6. Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Scale of Operation
  • 13.7. Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Size of Manufacturers
  • 13.8. Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Geography
    • 13.8.1. Vaccine Contract Manufacturing Market in North America, 2019-2030
      • 13.8.1.1. Vaccine Contract Manufacturing Market in the US, 2019-2030
      • 13.8.1.2. Vaccine Contract Manufacturing Market in Rest of North America, 2019-2030
      • 13.8.1.3. Vaccine Contract Manufacturing Market in North America for Mammalian Cell-based Operations, 2019-2030
      • 13.8.1.4. Vaccine Contract Manufacturing Market in North America for Microbial Cell-based Operations, 2019-2030
      • 13.8.1.5. Vaccine Contract Manufacturing Market in North America for Other Expression System-based Operations, 2019-2030
      • 13.8.1.6. Vaccine Contract Manufacturing Market in North America for Preclinical / Clinical Scale Operations, 2019-2030
      • 13.8.1.7. Vaccine Contract Manufacturing Market in North America for Commercial Operations, 2019-2030
      • 13.8.1.8. Vaccine Contract Manufacturing Market in North America for Small-sized Companies, 2019-2030
      • 13.8.1.9. Vaccine Contract Manufacturing Market in North America for Mid-sized Companies, 2019-2030
      • 13.8.1.10. Vaccine Contract Manufacturing Market in North America for Large / Very Large Companies, 2019-2030
    • 13.8.2. Vaccine Contract Manufacturing Market in Europe, 2019-2030
      • 13.8.2.1. Vaccine Contract Manufacturing Market in Italy, 2019-2030
      • 13.8.2.2. Vaccine Contract Manufacturing Market in Germany, 2019-2030
      • 13.8.2.3. Vaccine Contract Manufacturing Market in France, 2019-2030
      • 13.8.2.4. Vaccine Contract Manufacturing Market in Spain, 2019-2030
      • 13.8.2.5. Vaccine Contract Manufacturing Market in the UK, 2019-2030
      • 13.8.2.6. Vaccine Contract Manufacturing Market in Rest of Europe, 2019-2030
      • 13.8.2.7. Vaccine Contract Manufacturing Market in Europe for Mammalian Cell-based Operations, 2019-2030
      • 13.8.2.8. Vaccine Contract Manufacturing Market in Europe for Microbial Cell-based Operations, 2019-2030
      • 13.8.2.9. Vaccine Contract Manufacturing Market in Europe for Other Expression System-based Operations, 2019-2030
      • 13.8.2.10. Vaccine Contract Manufacturing Market in Europe for Preclinical / Clinical Operations, 2019-2030
      • 13.8.2.11. Vaccine Contract Manufacturing Market in Europe for Commercial Operations, 2019-2030
      • 13.8.2.12. Vaccine Contract Manufacturing Market in Europe for Small-sized Companies, 2019-2030
      • 13.8.2.13. Vaccine Contract Manufacturing Market in Europe for Mid-sized Companies, 2019-2030
      • 13.8.2.14. Vaccine Contract Manufacturing Market in Europe for Large / Very Large Companies, 2019-2030
    • 13.8.3. Vaccine Contract Manufacturing Market in Asia and Rest of the World, 2019-2030
      • 13.8.3.1. Vaccine Contract Manufacturing Market in China, 2019-2030
      • 13.8.3.2. Vaccine Contract Manufacturing Market in India, 2019-2030
      • 13.8.3.3. Vaccine Contract Manufacturing Market in South Korea, 2019-2030
      • 13.8.3.4. Vaccine Contract Manufacturing Market in Japan, 2019-2030
      • 13.8.3.5. Vaccine Contract Manufacturing Market in Australia, 2019-2030
      • 13.8.3.6. Vaccine Contract Manufacturing Market in Rest of Asia and Other Regions, 2019-2030
      • 13.8.3.7. Vaccine Contract Manufacturing Market in Asia and Rest of the World for Mammalian Cell-based Operations, 2019-2030
      • 13.8.3.8. Vaccine Contract Manufacturing Market in Asia and Rest of the World for Microbial Cell-based Operations, 2019-2030
      • 13.8.3.9. Vaccine Contract Manufacturing Market in Asia and Rest of the World for Other Expression System-based Operations, 2019-2030
      • 13.8.3.10. Vaccine Contract Manufacturing Market in Asia and Rest of the World for Preclinical / Clinical Operations, 2019-2030
      • 13.8.3.11. Vaccine Contract Manufacturing Market in Asia and Rest of the World for Commercial Operations, 2019-2030
      • 13.8.3.12. Vaccine Contract Manufacturing Market in Asia and Rest of the World for Small-sized Companies, 2019-2030
      • 13.8.3.13. Vaccine Contract Manufacturing Market in Asia and Rest of the World for Mid-sized Companies, 2019-2030
      • 13.8.3.14. Vaccine Contract Manufacturing Market in Asia and Rest of the World for Large / Very Large Companies, 2019-2030

14. SWOT ANALYSIS

  • 14.1 Chapter Overview
  • 14.2. Strengths
  • 14.3. Weaknesses
  • 14.4. Opportunities
  • 14.5. Threats
  • 14.6. Comparison of Swot Factors
  • 14.7. Concluding Remarks

15. FUTURE TRENDS

  • 15.1. Chapter Overview
  • 15.2. Adoption of Innovative Technologies to Drive Growth
  • 15.3. Shift to Single Use Systems and Components
  • 15.4. The Advent of Virus-like Particles (VLPs)
  • 15.5. Growing Investments in Existing Infrastructure
  • 15.6. Evolving Client / Sponsor and CMO / CDMO Relationships
  • 15.7. Business Acquisition and Consolidation Activity

16. EXECUTIVE INSIGHTS

  • 16.1. Chapter Overview
  • 16.2. Batavia Biosciences
    • 16.2.1 Company Snapshot
    • 16.2.2 Interview Transcript: Menzo Havenga, CEO and Claire Otjes, Marketing Manager
  • 16.3. Goodwin Biotechnology
    • 16.3.1. Company Snapshot
    • 16.3.2 Interview Transcript: David C Cunningham, Director Corporate Development
  • 16.4. Statens Serum Institut
    • 16.4.1. Company Snapshot
    • 16.4.2 Interview Transcript: Ingrid Cromann, Director - Vaccine Development
  • 16.5. Novasep Synthesis
    • 16.5.1. Company Snapshot
    • 16.5.2 Interview Transcript: Kevin Daley, Director Pharmaceuticals
  • 16.6. ProBioGen
    • 16.6.1. Company Snapshot
    • 16.6.2 Interview Transcript: Oliver Schub, Senior Business Development Manager
  • 16.7. Wacker Biotech
    • 16.7.1 Company Snapshot
    • 16.7.2 Interview Transcript: Sebastian Schuck, Head of Business Development

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

  • Figure 3.1: Differences Between Vaccines and Small Molecule Drugs
  • Figure 3.2: Classification of Vaccines
  • Figure 3.3: Vaccine Manufacturing Process
  • Figure 3.4: Key Steps in Vaccine Transportation
  • Figure 3.5: Types of Third-Party Service Providers in the Pharmaceutical Industry
  • Figure 3.6: Commonly Outsourced Vaccine Development Operations
  • Figure 3.7: Key Considerations for Selecting a CMO Partner
  • Figure 3.8: Risks and Challenges Associated with Contract Manufacturing
  • Figure 4.1: Vaccine CMOs: Distribution by Year of Establishment
  • Figure 4.2: Vaccine CMOs: Distribution by Size of Employee Base
  • Figure 4.3: Vaccine CMOs: Distribution by Location of Headquarters (Region-wise)
  • Figure 4.4: Vaccine CMOs: Distribution by Location of Headquarters (Country-wise)
  • Figure 4.5: Vaccine CMOs: Distribution by Location of Manufacturing Facility (Region-wise)
  • Figure 4.6: Vaccine CMOs: Distribution by Location of Manufacturing Facility (Country-wise)
  • Figure 4.7: Vaccine CMOs: Distribution by Type of Services Offered
  • Figure 4.8: Vaccine CMOs: Distribution by Scale of Operation
  • Figure 4.9: Vaccine CMOs: Distribution by Expression System Used
  • Figure 4.10: Vaccine CMOs: Distribution by Type of Vaccines Manufactured
  • Figure 5.1.: Competitiveness Analysis of Vaccine Contract Manufacturers in North America
  • Figure 5.2.: Competitiveness Analysis of North American Service Providers Offering Contract Manufacturing of Vaccines based on Mammalian Expression
  • Figure 5.3. Competitiveness Analysis of North American Service Providers Offering Contract Manufacturing of Vaccines based on Microbial Expression System
  • Figure 5.4.: Competitiveness Analysis of North American Service Providers Offering Contract Manufacturing of Vaccines based on Other Expression System
  • Figure 5.5.: Competitiveness Analysis of Vaccine Contract Manufacturers in Europe
  • Figure 5.6.: Competitiveness Analysis of European Service Providers Offering Contract Manufacturing of Vaccines based on Mammalian Expression System
  • Figure 5.7.: Competitiveness Analysis of European Service Providers Offering Contract Manufacturing of Vaccines based on Microbial Expression System
  • Figure 5.8.: Competitiveness Analysis of European Service Providers Offering Contract Manufacturing of Vaccines based on Other Expression System
  • Figure 5.9. Competitiveness Analysis of Vaccine Contract Manufacturers in Asia-Pacific
  • Figure 5.10.: Competitiveness Analysis of Asia Pacific Service Providers Offering Contract Manufacturing of Vaccines based on Mammalian Expression System
  • Figure 5.11.: Competitiveness Analysis of Asia Pacific Service Providers Offering Contract Manufacturing of Vaccines based on Microbial Expression System
  • Figure 5.12.: Competitiveness Analysis of Asia Pacific Service Providers Offering Contract Manufacturing of Vaccines based on Other Expression System
  • Figure 6.1: AMRI: Annual Revenues, 2012- Q1 2017 (USD Million)
  • Figure 6.2: AMRI: Overview of Service Portfolio
  • Figure 6.3: Catalent: Revenues, 2013 - Q1 2019 (USD Million)
  • Figure 6.4: Catalent: Revenues by Business Divisions, 2018 (USD Million)
  • Figure 6.5: Catalent: Vaccine Manufacturing Services Portfolio
  • Figure 6.6: Charles River Laboratories: Annual Revenues, 2011-2018 (USD Billion)
  • Figure 6.7: Charles River Laboratories: Distribution of Revenues by Business Segments, 2018 (USD Billion)
  • Figure 6.8: Charles River Laboratories: Products and Services
  • Figure 6.9: Meridian Life Science: Annual Revenues, 2013- H1 2019 (USD Million)
  • Figure 6.10: Merck: Annual Revenues, 2012 -2018 (EUR Billion)
  • Figure 6.11: Merck: Distribution of Revenues by Business Segments, 2018 (EUR Billion)
  • Figure 6.12: SAFC: Contract Manufacturing Support Services
  • Figure 6.13: SAFC Carlsbad Facility: Vaccine Manufacturing Services
  • Figure 7.1: Eurogentec: Manufacturing Technologies and Capabilities
  • Figure 7.2: IDT Biologika: Vaccine-related Service Portfolio
  • Figure 7.1: Lonza: Annual Revenues, 2012-2018 (CHF Million)
  • Figure 7.2: Lonza: Vaccine Manufacturing Services Portfolio
  • Figure 8.1: Hong Kong Institute of Biotechnology: Service Portfolio
  • Figure 8.2: WuXi Biologics: Annual Revenues, 2014-2018 (RMB Million)
  • Figure 8.3: WuXi Biologics: Vaccine Development Services
  • Figure 8.4: WuXi Biologics: Vaccine Testing Services
  • Figure 9.1: Partnerships and Collaborations: Cumulative Trend by Year, 2013-2019
  • Figure 9.2: Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 9.3: Partnerships and Collaborations: Trend by Type of Partnership and Year (2013-2018)
  • Figure 9.4: Partnerships and Collaborations: Distribution by Type of Vaccines
  • Figure 9.5: Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partnership
  • Figure 9.6: Partnerships and Collaborations: Distribution by Scale of Operation and Type of Partnership
  • Figure 9.7: Partnerships and Collaborations: Most Active Players
  • Figure 9.8: Partnerships and Collaborations: Regional Distribution
  • Figure 9.9: Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Figure 10.1: Facility Expansions: Distribution by Year, 2013-2019
  • Figure 10.2: Facility Expansions: Distribution by Type of Expansion
  • Figure 10.3: Facility Expansions: Distribution by Scale of Operation and Type of Expansion
  • Figure 10.4: Facility Expansions: Distribution by Geography and Year, 2013-2019
  • Figure 10.5: Facility Expansions: Distribution by Company Headquarters and Company Size
  • Figure 10.6: Facility Expansions: Distribution by Location of Facility and Type of Expansion
  • Figure 10.7: Facility Expansions: Distribution by Type of Services Offered
  • Figure 10.8: Facility Expansions: Distribution by Type of Services and Type of Expansion
  • Figure 10.9: Facility Expansions: Most Active Players
  • Figure 11.1: Vaccine Contract Manufacturing Market: Global Capacity: Distribution by Range of Installed Capacity
  • Figure 11.2: Capacity Analysis: Global Vaccine Contract Manufacturing Capacity by Size of CMOs
  • Figure 11.3: Capacity Analysis: Global Vaccine Contract Manufacturing Capacity based on Expression System
  • Figure 11.4: Capacity Analysis: Global Vaccine Contract Manufacturing Capacity based on Scale of Manufacturing
  • Figure 11.5: Capacity Analysis: Regional Distribution of Vaccine CMOs
  • Figure 11.6: Capacity Analysis: Vaccine Contract Manufacturing Capacity of the US
  • Figure 11.7: Capacity Analysis: Regional Vaccine Contract Manufacturing Capacity of Canada
  • Figure 11.8: Capacity Analysis: Regional Vaccine Contract Manufacturing Capacity of the UK
  • Figure 11.9: Capacity Analysis: Regional Vaccine Contract Manufacturing Capacity of Germany
  • Figure 11.10: Capacity Analysis: Regional Vaccine Contract Manufacturing Capacity of France
  • Figure 11.11: Capacity Analysis: Regional Vaccine Contract Manufacturing Capacity of Italy
  • Figure 11.12: Capacity Analysis: Regional Vaccine Contract Manufacturing Capacity of Spain
  • Figure 11.13: Capacity Analysis: Regional Vaccine Contract Manufacturing Capacity of rest of Europe
  • Figure 11.14: Capacity Analysis: Regional Vaccine Contract Manufacturing Capacity of South Korea
  • Figure 11.15: Capacity Analysis: Regional Vaccine Contract Manufacturing Capacity of India
  • Figure 11.16: Capacity Analysis: Regional Vaccine Contract Manufacturing Capacity of China
  • Figure 11.17: Capacity Analysis: Regional Vaccine Contract Manufacturing Capacity of Japan
  • Figure 11.18: Capacity Analysis: Regional Vaccine Contract Manufacturing Capacity of Rest of Asia and Middle East
  • Figure 12.1: Global Clinical Demand for Vaccines: Cumulative Distribution of Trials by Registration Year
  • Figure 12.2: Global Clinical Demand for Vaccines: Distribution of Trials by Type of Vaccines
  • Figure 12.3: Global Clinical Demand for Vaccines: Distribution of Trials by Phase
  • Figure 12.4: Global Clinical Demand for Vaccines: Distribution of Trials by Status
  • Figure 12.5: Global Clinical Demand for Vaccines: Geographical Distribution of Trials (Country-Wise)
  • Figure 12.6: Global Clinical Demand for Vaccines: Geographical Distribution of Trials by Status and Phase
  • Figure 12.7: Global Clinical Demand for Vaccines: Distribution of Trials by Type of Sponsors / Collaborators
  • Figure 12.8: Global Clinical Demand for Vaccines: Most Active Industry Players in Terms of Number of Trials Conducted
  • Figure 12.9: Global Clinical Demand for Vaccines: Most Active Non-Industry Players in Terms of Number of Trials Conducted
  • Figure 12.10: Global Clinical Demand for Vaccines: Geographical Distribution of Enrolled Patient Population (Country-Wise)
  • Figure 12.11: Global Clinical Demand for Vaccines: Geographical Distribution of Enrolled Patient Population by Type of Vaccine
  • Figure 12.12: Global Clinical Demand for Vaccines: Annual Demand for Vaccines (in Liters)
  • Figure 13.1: Overall Vaccine Contract Manufacturing Market, 2019-2030 (USD Million)
  • Figure 13.2: Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Type of Services Offered (USD Billion)
  • Figure 13.3: Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Expression System Used (USD Million)
  • Figure 13.4: Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Scale of Operation (USD Million)
  • Figure 13.5: Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Size of Employee Base of Contract Manufacturers (USD Million)
  • Figure 13.6: Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Geography (USD Million)
  • Figure 13.7: Vaccine Contract Manufacturing Market in North America, 2019-2030 (USD Million)
  • Figure 13.8: Vaccine Contract Manufacturing Market in the US, 2019-2030 (USD Million)
  • Figure 13.9: Vaccine Contract Manufacturing Market in Rest of North America, 2019-2030 (USD Million)
  • Figure 13.10: Vaccine Contract Manufacturing Market in North America for Mammalian Cell-based Operations, 2019-2030 (USD Million)
  • Figure 13.11: Vaccine Contract Manufacturing Market in North America for Microbial Cell-based Operations, 2019-2030 (USD Million)
  • Figure 13.12: Vaccine Contract Manufacturing Market in North America for Other Expression System-based Operations, 2019-2030 (USD Million)
  • Figure 13.13: Vaccine Contract Manufacturing Market in North America for Preclinical / Clinical Scale Operations, 2019-2030 (USD Million)
  • Figure 13.14: Vaccine Contract Manufacturing Market in North America for Commercial Operations, 2019-2030 (USD Million)
  • Figure 13.15: Vaccine Contract Manufacturing Market in North America for Small-sized Companies, 2019-2030 (USD Million)
  • Figure 13.16: Vaccine Contract Manufacturing Market in North America for Mid-sized Companies, 2019-2030 (USD Million)
  • Figure 13.17: Vaccine Contract Manufacturing Market in North America for Large / Very Large Companies, 2019-2030 (USD Million)
  • Figure 13.18: Vaccine Contract Manufacturing Market in Europe, 2019-2030 (USD Million)
  • Figure 13.19: Vaccine Contract Manufacturing Market in Italy, 2019-2030 (USD Million)
  • Figure 13.20: Vaccine Contract Manufacturing Market in Germany, 2019-2030 (USD Million)
  • Figure 13.21 Vaccine Contract Manufacturing Market in France, 2019-2030 (USD Million)
  • Figure 13.22: Vaccine Contract Manufacturing Market in Spain, 2019-2030 (USD Million)
  • Figure 13.23: Vaccine Contract Manufacturing Market in the UK, 2019-2030 (USD Million)
  • Figure 13.24: Vaccine Contract Manufacturing Market in Rest of Europe, 2019-2030 (USD Million)
  • Figure 13.25: Vaccine Contract Manufacturing Market in Europe for Mammalian Cell-based Operations, 2019-2030 (USD Million)
  • Figure 13.26: Vaccine Contract Manufacturing Market in Europe for Microbial Cell-based Operations, 2019-2030 (USD Million)
  • Figure 13.27: Vaccine Contract Manufacturing Market in Europe for Other Expression System-based Operations, 2019-2030 (USD Million)
  • Figure 13.28: Vaccine Contract Manufacturing Market in Europe for Preclinical / Clinical Operations, 2019-2030 (USD Million)
  • Figure 13.29: Vaccine Contract Manufacturing Market in Europe for Commercial Operations, 2019-2030 (USD Million)
  • Figure 13.30: Vaccine Contract Manufacturing Market in Europe for Small-sized Companies, 2019-2030 (USD Million)
  • Figure 13.31 Vaccine Contract Manufacturing Market in Europe for Mid-sized Companies, 2019-2030 (USD Million)
  • Figure 13.32: Vaccine Contract Manufacturing Market in Europe for Large / Very Large Companies, 2019-2030 (USD Million)
  • Figure 13.33: Vaccine Contract Manufacturing Market in Asia and Rest of the World, 2019-2030 (USD Million)
  • Figure 13.34: Vaccine Contract Manufacturing Market in China, 2019-2030 (USD Million)
  • Figure 13.35: Vaccine Contract Manufacturing Market in India, 2019-2030 (USD Million)
  • Figure 13.36: Vaccine Contract Manufacturing Market in South Korea, 2019-2030 (USD Million)
  • Figure 13.37: Vaccine Contract Manufacturing Market in Japan, 2019-2030 (USD Million)
  • Figure 13.38: Vaccine Contract Manufacturing Market in Australia, 2019-2030 (USD Million)
  • Figure 13.39: Vaccine Contract Manufacturing Market in Rest of Asia and Other Regions, 2019-2030 (USD Million)
  • Figure 13.40: Vaccine Contract Manufacturing Market in Asia and Rest of the World for Mammalian Cell-based Operations, 2019-2030 (USD Million)
  • Figure 13.41: Vaccine Contract Manufacturing Market in Asia and Rest of the World for Microbial Cell-based Operations, 2019-2030 (USD Million)
  • Figure 13.42: Vaccine Contract Manufacturing Market in Asia and Rest of the World for Other Expression System-based Operations, 2019-2030 (USD Million)
  • Figure 13.43: Vaccine Contract Manufacturing Market in Asia and Rest of the World for Preclinical / Clinical Operations, 2019-2030 (USD Million)
  • Figure 13.44: Vaccine Contract Manufacturing Market in Asia and Rest of the World for Commercial Operations, 2019-2030 (USD Million)
  • Figure 13.45: Vaccine Contract Manufacturing Market in Asia and Rest of the World for Small-sized Companies, 2019-2030 (USD Million)
  • Figure 13.46: Vaccine Contract Manufacturing Market in Asia and Rest of the World for Mid-sized Companies, 2019-2030 (USD Million)
  • Figure 13.47: Vaccine Contract Manufacturing Market in Asia and Rest of the World for Large / Very Large Companies, 2019-2030 (USD Million)
  • Figure 14.1: Vaccine Contract Manufacturing: SWOT Analysis
  • Figure 14.2 Comparison of SWOT Factors: Harvey Ball Analysis

List of Tables

  • Table 3.1 Classification of Vaccines based on Method of Development
  • Table 3.2 Live Attenuated Vaccines: Commonly Reported Adverse Events
  • Table 3.3 Inactivated Vaccines: Commonly Reported Adverse Events
  • Table 3.4 Subunit Vaccines: Commonly Reported Adverse Events
  • Table 3.5 Toxoid Vaccines: Commonly Reported Adverse Events
  • Table 3.6 Vaccine Excipients and their Functions
  • Table 4.1 Vaccine Contract Manufacturers: List of Service Providers
  • Table 4.2 Vaccine CMOs: Information on Type of Services Offered
  • Table 4.3 Vaccine CMOs: Information on Scale of Operation
  • Table 4.4 Vaccine CMOs: Information on Expression System Used
  • Table 4.5 Vaccine CMOs: Information on Type of Vaccines Manufactured
  • Table 6.1 Vaccine CMOs: List of Profiled Companies (North America)
  • Table 6.2 AMRI (OsoBio): Company Overview
  • Table 6.3 AMRI (OsoBio): Recent Partnerships
  • Table 6.4 Catalent Biologics: Company Overview
  • Table 6.5 Catalent: Biologics Manufacturing and Laboratory Facilities
  • Table 6.6 Catalent: Recent Partnerships
  • Table 6.7 Charles River Laboratories: Recent Partnerships
  • Table 6.8 Charles River Laboratories: Future Outlook
  • Table 6.9 Meridian Life Science: Recent Partnerships
  • Table 6.10 BioReliance: Company Overview
  • Table 6.11 Merck: Recent Partnerships
  • Table 7.1 Vaccine CMOs: List of Profiled Companies (Europe)
  • Table 7.2 Cobra Biologics: Recent Partnerships
  • Table 7.3 IDT Biologika: Recent Partnerships
  • Table 7.4 Lonza: Company Overview
  • Table 7.5 Lonza: Recent Partnerships
  • Table 8.1 Vaccine CMOs: List of Profiled Companies (Emerging Regions)
  • Table 8.2 Hong Kong Institute of Biotechnology: Vaccine Contract Manufacturing Services
  • Table 8.3 WuXi Biologics: Biologics Development and Manufacturing Services
  • Table 8.4 WuXi Biologics: Recent Partnerships
  • Table 8.5 Bharat Biotech: Recent Partnerships
  • Table 8.6 Biological E: Recent Partnerships
  • Table 9.1 Vaccine Contract Manufacturing Market: Partnerships and Collaborations, 2013-2019
  • Table 10.1 Vaccine Contract Manufacturing Market: List of Recent Expansions, 2013-2019
  • Table 10.2 Expansions: Information on Types of Services
  • Table 14.1 Capacity Analysis: CMO Size Adjustments based on Capacity
  • Table 14.2 Capacity Analysis: CMO Size Adjustments based on Size of Employee Base
  • Table 14.3 Capacity Analysis: Key Assumptions and Inputs
  • Table 14.4 Capacity Analysis: Global Contract Vaccine Manufacturing Capacity
  • Table 14.5 Capacity Analysis: Regional Contract Vaccine Manufacturing Capacity
  • Table 17.1 Vaccine CMOs: Distribution by Year of Establishment
  • Table 17.2 Vaccine CMOs: Distribution by Size of Employee Base
  • Table 17.3 Vaccine CMOs: Distribution by Location of Headquarters (Region-wise)
  • Table 17.4 Vaccine CMOs: Distribution by Location of Headquarters (Country-wise)
  • Table 17.5 Vaccine CMOs: Distribution by Location of Manufacturing Facility (Region-wise)
  • Table 17.6 Vaccine CMOs: Distribution by Location of Manufacturing Facility (Country-wise)
  • Table 17.7 Vaccine CMOs: Distribution by Type of Services Offered
  • Table 17.8 Vaccine CMOs: Distribution by Scale of Operation
  • Table 17.9 Vaccine CMOs: Distribution by Expression System Used
  • Table 17.10 Vaccine CMOs: Distribution by Type of Vaccines Manufactured
  • Table 17.11 AMRI: Annual Revenues (USD Million)
  • Table 17.12 Catalent: Annual Revenues (USD Million)
  • Table 17.13 Catalent: Annual Revenues by Business Divisions (USD Million)
  • Table 17.14 Charles River Laboratories: Annual Revenues (USD Billion)
  • Table 17.15 Charles River Laboratories: Distribution of Revenues by Business Segments (USD Billion)
  • Table 17.16 Meridian Life Science: Annual Revenues (USD Million)
  • Table 17.17 Merck: Annual Revenues (EUR Billion)
  • Table 17.18 Lonza: Annual Revenues (CHF Billion)
  • Table 17.19 Wuxi Biologics: Annual Revenues (RMB Million)
  • Table 17.20 Wuxi Biologics: Annual Revenues by Regions of Operation (RMB million)
  • Table 17.21. Partnerships and Collaborations: Distribution by Year, 2013-2019
  • Table 17.22. Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 17.23. Partnerships and Collaborations: Distribution by Type of Partnership and Year
  • Table 17.24. Partnerships and Collaborations: Distribution by Type of Vaccines
  • Table 17.25. Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partnership
  • Table 17.26. Partnerships and Collaborations: Distribution by Scale of Operation and Type of Partnership
  • Table 17.27. Partnerships and Collaborations: Most Active Players
  • Table 17.28. Partnerships and Collaborations: Distribution by Geographical Location
  • Table 17.29. Facility Expansions: Distribution by Year, 2013-2019
  • Table 17.30. Facility Expansions: Distribution by Type of Expansion
  • Table 17.31. Facility Expansions: Distribution by Scale of Operation and Type of Expansion
  • Table 17.32. Facility Expansions: Distribution by Distribution by Company Headquarters and Company Size
  • Table 17.33. Facility Expansions: Distribution by Location of Facility and Type of Expansion
  • Table 17.34. Facility Expansions: Distribution by Types of Services Offered
  • Table 17.35. Facility Expansions: Distribution by Types of Services and Type of Expansion
  • Table 17.36. Facility Expansions: Most Active Players
  • Table 17.37 Capacity Analysis: Global Contract Biomanufacturing Capacity by Size of CMOs
  • Table 17.38 Capacity Analysis: Global Vaccine Contract Manufacturing Capacity based on Expression System
  • Table 17.39 Capacity Analysis: Global Vaccine Contract Manufacturing Capacity based on Scale of Manufacturing
  • Table 17.40 Overall Vaccine Contract Manufacturing Market, 2019-2030 (USD Million)
  • Table 17.41 Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Type of Services Offered (USD Billion)
  • Table 17.42 Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Expression System Used (USD Billion)
  • Table 17.43 Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Scale of Operation (USD Billion)
  • Table 17.44 Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Size of Employee Base of Contract Manufacturers (USD Billion)
  • Table 17.45 Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Geography (USD Billion)
  • Table 17.46 Vaccine Contract Manufacturing Market in North America, 2019-2030 (USD Million)
  • Table 17.47 Vaccine Contract Manufacturing Market in the US, 2019-2030 (USD Million)
  • Table 17.48 Vaccine Contract Manufacturing Market in Rest of North America, 2019-2030 (USD Million)
  • Table 17.49 Vaccine Contract Manufacturing Market in North America for Mammalian Cell-based Operations, 2019-2030 (USD Million)
  • Table 17.50 Vaccine Contract Manufacturing Market in North America for Microbial Cell-based Operations, 2019-2030 (USD Million)
  • Table 17.51 Vaccine Contract Manufacturing Market in North America for Other Expression System-based Operations, 2019-2030 (USD Million)
  • Table 17.52 Vaccine Contract Manufacturing Market in North America for Preclinical / Clinical Scale Operations, 2019-2030 (USD Million)
  • Table 17.53 Vaccine Contract Manufacturing Market in North America for Commercial Operations, 2019-2030 (USD Million)
  • Table 17.54 Vaccine Contract Manufacturing Market in North America for Small-sized Companies, 2019-2030 (USD Million)
  • Table 17.55 Vaccine Contract Manufacturing Market in North America for Mid-sized Companies, 2019-2030 (USD Million)
  • Table 17.56 Vaccine Contract Manufacturing Market in North America for Large / Very Large Companies, 2019-2030 (USD Million)
  • Table 17.57 Vaccine Contract Manufacturing Market in Europe, 2019-2030 (USD Million)
  • Table 17.58 Vaccine Contract Manufacturing Market in Italy, 2019-2030 (USD Million)
  • Table 17.59 Vaccine Contract Manufacturing Market in Germany, 2019-2030 (USD Million)
  • Table 17.60 Vaccine Contract Manufacturing Market in France, 2019-2030 (USD Million)
  • Table 17.61 Vaccine Contract Manufacturing Market in Spain, 2019-2030 (USD Million)
  • Table 17.62 Vaccine Contract Manufacturing Market in the UK, 2019-2030 (USD Million)
  • Table 17.63 Vaccine Contract Manufacturing Market in Rest of Europe, 2019-2030 (USD Million)
  • Table 17.64 Vaccine Contract Manufacturing Market in Europe for Mammalian Cell-based Operations, 2019-2030 (USD Million)
  • Table 17.65 Vaccine Contract Manufacturing Market in Europe for Microbial Cell-based Operations, 2019-2030 (USD Million)
  • Table 17.66 Vaccine Contract Manufacturing Market in Europe for Other Expression System-based Operations, 2019-2030 (USD Million)
  • Table 17.67 Vaccine Contract Manufacturing Market in Europe for Preclinical / Clinical Operations, 2019-2030 (USD Million)
  • Table 17.68 Vaccine Contract Manufacturing Market in Europe for Commercial Operations, 2019-2030 (USD Million)
  • Table 17.69 Vaccine Contract Manufacturing Market in Europe for Small-sized Companies, 2019-2030 (USD Million)
  • Table 17.70 Vaccine Contract Manufacturing Market in Europe for Mid-sized Companies, 2019-2030 (USD Million)
  • Table 17.71 Vaccine Contract Manufacturing Market in Europe for Large / Very Large Companies, 2019-2030 (USD Million)
  • Table 17.72 Vaccine Contract Manufacturing Market in Asia and Rest of the World, 2019-2030 (USD Million)
  • Table 17.73 Vaccine Contract Manufacturing Market in China, 2019-2030 (USD Million)
  • Table 17.74 Vaccine Contract Manufacturing Market in India, 2019-2030 (USD Million)
  • Table 17.75 Vaccine Contract Manufacturing Market in South Korea, 2019-2030 (USD Million)
  • Table 17.76 Vaccine Contract Manufacturing Market in Japan, 2019-2030 (USD Million)
  • Table 17.77 Vaccine Contract Manufacturing Market in Australia, 2019-2030 (USD Million)
  • Table 17.78 Vaccine Contract Manufacturing Market in Rest of Asia and Other Regions, 2019-2030 (USD Million)
  • Table 17.79 Vaccine Contract Manufacturing Market in Asia and Rest of the World for Mammalian Cell-based Operations, 2019-2030 (USD Million)
  • Table 17.80 Vaccine Contract Manufacturing Market in Asia and Rest of the World for Microbial Cell-based Operations, 2019-2030 (USD Million)
  • Table 17.81 Vaccine Contract Manufacturing Market in Asia and Rest of the World for Other Expression System-based Operations, 2019-2030 (USD Million)
  • Table 17.82 Vaccine Contract Manufacturing Market in Asia and Rest of the World for Preclinical / Clinical Operations, 2019-2030 (USD Million)
  • Table 17.83 Vaccine Contract Manufacturing Market in Asia and Rest of the World for Commercial Operations, 2019-2030 (USD Million)
  • Table 17.84 Vaccine Contract Manufacturing Market in Asia and Rest of the World for Small-sized Companies, 2019-2030 (USD Million)
  • Table 17.85 Vaccine Contract Manufacturing Market in Asia and Rest of the World for Mid-sized Companies, 2019-2030 (USD Million)
  • Table 17.86 Vaccine Contract Manufacturing Market in Asia and Rest of the World for Large / Very Large Companies, 2019-2030 (USD Million)

List of Companies

  • 1. 3P Biopharmaceuticals
  • 2. Acambis
  • 3. Accugenix
  • 4. Actavis
  • 5. Advanced BioScience Laboratories
  • 6. Advaxis
  • 7. Aeras
  • 8. AGC Biologics
  • 9. AJ Biologics
  • 10. Albany Molecular Research
  • 11. Alexion Pharmaceuticals
  • 12. Algonomics
  • 13. Altaris Capital Partners
  • 14. AmbioPharm
  • 15. AnaSpec
  • 16. Aptuit
  • 17. Association for Assessment and Accreditation of Laboratory Animal Care
  • 18. Avid Bioservices
  • 19. Bachem
  • 20. Batavia Biosciences
  • 21. Battelle
  • 22. Bavarian Nordic
  • 23. Baxter BioPharma Solutions
  • 24. Baylor Institute for Immunology Research
  • 25. BD Biosciences
  • 26. Benchmark Vaccines
  • 27. Bharat Biotech
  • 28. Bill & Melinda Gates Foundation
  • 29. Bilthoven Biologicals
  • 30. Biocell
  • 31. Biocon
  • 32. BioConnections
  • 33. BioConvergence
  • 34. Biofabri
  • 35. Bioline
  • 36. Biological E
  • 37. BioMARC
  • 38. Biomay
  • 39. Biomedical Advanced Research and Development Authority
  • 40. BioMotiv
  • 41. BiondVax Pharmaceuticals
  • 42. BioReliance
  • 43. BioTechnique
  • 44. Biotechnology and Biological Sciences Research Council
  • 45. Biovest International
  • 46. Birgi Mefar Group
  • 47. Boehringer Ingelheim
  • 48. Boston Children's Hospital
  • 49. Bristol-Myers Squibb
  • 50. Bryllan
  • 51. CALIXAR
  • 52. Canadian Animal Health Institute
  • 53. Canadian Council on Animal Care
  • 54. Catalent
  • 55. Celsis International
  • 56. Cetus
  • 57. CEVEC Pharmaceuticals
  • 58. Charles River Biopharmaceutical Services
  • 59. Charles River Laboratories
  • 60. Chimera Biotec
  • 61. China Agricultural University
  • 62. China National Biotec Group
  • 63. Chinese Center for Disease Control and Prevention
  • 64. Chinese University of Hong Kong
  • 65. Chiron Behring Vaccines (acquired by Bharat Biotech)
  • 66. Cobra Biologics
  • 67. Cook Pharmica
  • 68. Crucell Sweden
  • 69. Cytovance Biologics
  • 70. Daiichi Sankyo
  • 71. Deltamune
  • 72. Dr. Reddy's Laboratories
  • 73. Dyadic International
  • 74. EGYVAC
  • 75. Emergent BioSolutions
  • 76. Engineering and Physical Sciences Research Council
  • 77. EuBiologics
  • 78. Eurogentec
  • 79. European Medicines Agency
  • 80. ExpreS2ion Biotech Holding
  • 81. Exxell BIO
  • 82. Federation of Indian Chambers of Commerce and Industry
  • 83. Florida Biologix
  • 84. French National Agency for Research on AIDS and Viral Hepatitis
  • 85. Friedrich-Loeffler-Institut
  • 86. FUJIFILM Diosynth Biotechnologies
  • 87. Gallant Custom Laboratories
  • 88. Gamma Vaccines
  • 89. GAVI
  • 90. Genentech
  • 91. GENEWIZ
  • 92. Genzyme Polyclonals
  • 93. GlaxoSmithKline
  • 94. GNH India Pharmaceuticals
  • 95. Goodwin Biotechnology
  • 96. Grand River Aseptic Manufacturing
  • 97. Greenpak Biotech
  • 98. Grifols
  • 99. Guangxi Veterinary Research Institute
  • 100. Guangzhou Air force Hospital
  • 101. Haffkine Institute
  • 102. HALIX
  • 103. Harbin Veterinary Research Institute
  • 104. Hennepin Healthcare Research Institute
  • 105. HLL Biotech
  • 106. Hong Kong Institute of Biotechnology
  • 107. IDT Biologika
  • 108. ImevaX
  • 109. Immune Design
  • 110. Immune Targeting Systems (acquired by Vaxin)
  • 111. ImmunoSite Technologies
  • 112. ImVisioN Therapeutics
  • 113. Index Ventures
  • 114. Indian Council of Medical Research
  • 115. Indian Immunologicals
  • 116. Infectious Disease Research Institute
  • 117. Innovate UK
  • 118. Integrity Bio
  • 119. International Medica Foundation
  • 120. International Society for Pharmaceutical Engineering
  • 121. Interros
  • 122. Intervacc
  • 123. Inviragen (acquired by Takeda)
  • 124. Irvine Pharmaceutical Services (acquired by Nitto Avecia Pharma Services)
  • 125. Israel Institute for Biological Research
  • 126. Jubilant HollisterStier
  • 127. KABS Pharmaceutical Services
  • 128. Kalon Biotherapeutics
  • 129. Kaneka
  • 130. KBI Biopharma
  • 131. LigoCyte Pharmaceuticals
  • 132. Lonza
  • 133. Luina Bio
  • 134. Magellan BioScience Group
  • 135. MassBiologics
  • 136. Medicago
  • 137. Medicines and Healthcare products Regulatory Agency
  • 138. Merck
  • 139. Meridian Life Science
  • 140. Mitsubishi Gas Chemical
  • 141. Mitsubishi Tanabe Pharma
  • 142. Moderna Therapeutics
  • 143. Mymetics
  • 144. Najít Technologies
  • 145. National Avian Influenza Reference Laboratory
  • 146. National Heart, Lung, and Blood Institute
  • 147. National Institutes of Allergy and Infectious Diseases
  • 148. NewLink Genetics
  • 149. Norwegian Institute of Public Health
  • 150. Nouscom
  • 151. Novartis
  • 152. Novasep
  • 153. Novavax
  • 154. NPO Petrovax Pharm
  • 155. OctoPlus
  • 156. Okairos
  • 157. Oncotest
  • 158. Organization for Economic Cooperation and Development
  • 159. OSO BioPharmaceuticals Manufacturing
  • 160. Pacific GMP
  • 161. Panacea Biotec
  • 162. Paragon Bioservices
  • 163. PATH
  • 164. PaxVax
  • 165. Pfenex
  • 166. Pfizer
  • 167. Pfizer CentreOne
  • 168. PharmaPak
  • 169. PharmaSynth
  • 170. Premas Biotech
  • 171. Prime European Therapeuticals
  • 172. ProBioGen
  • 173. Protagen
  • 174. PX'Therapeutics
  • 175. QuiaPEG Pharmaceuticals
  • 176. RAFAGEN
  • 177. Recipharm
  • 178. Richter-Helm
  • 179. RIEMSER Pharma
  • 180. SAFC
  • 181. Sanofi Active Ingredient Solutions
  • 182. Sanofi Pasteur
  • 183. Sartorius Stedim Biotech
  • 184. Serum Institute of India
  • 185. Shandong Zhaoxin Bio-tech
  • 186. Shanghai Laboratory Animal Center
  • 187. ShangPharma Innovation
  • 188. SialoCarb
  • 189. Sichuan Agricultural University
  • 190. Sigma-Aldrich
  • 191. SK Chemicals
  • 192. Soligenix
  • 193. South China Agricultural University
  • 194. State Secretariat for Education, Research and Innovation
  • 195. Statens Serum Institut
  • 196. Stellar Biotechnologies
  • 197. Sumagen
  • 198. SynCo Bio Partners
  • 199. Synthelis
  • 200. Takeda Pharmaceuticals
  • 201. Temasek Life Sciences Ventures
  • 202. The Hong Kong Jockey Club Charities Trust
  • 203. Thermo Fisher Scientific
  • 204. Thomas Jefferson University
  • 205. Tianjin CanSino Biotechnology
  • 206. Transgene
  • 207. Unitech Pharma Group
  • 208. United States Army Medical Research Institute of Infectious Diseases
  • 209. Univercells
  • 210. University of Copenhagen
  • 211. University of Maryland
  • 212. University of Oxford
  • 213. University of Pennsylvania
  • 214. Upperton Pharma Solutions
  • 215. Vaccibody
  • 216. VACSERA
  • 217. Valerius Biopharma
  • 218. Valneva
  • 219. Vaxin
  • 220. Vetter Pharma
  • 221. VGXI
  • 222. Vibalogics
  • 223. Vivalis
  • 224. Vybion
  • 225. Waisman Biomanufacturing
  • 226. Walter Reed Army Institute of Research
  • 227. Wellcome Trust
  • 228. WIL Research
  • 229. World Trade Organization
  • 230. WuXi AppTec
  • 231. Wuxi Fortune Pharmaceutical
  • 232. Zoetis
Back to Top